A groundbreaking study published in Current Pharmaceutical Analysis has uncovered a potential therapeutic target for bortezomib-induced peripheral neuropathy (BIPN), a common and debilitating side ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback